Sibutramine: A serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

Annals of Pharmacotherapy

Volumn 33, Issue 9, 1999, Pages 968-978

  Luque, Carla A ^a   Rey, Jose A ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Inhibitors; Norepinephrine; Obesity; Serotonin

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ANOREXIA; CALORIC INTAKE; CONSTIPATION; DRUG EFFICACY; DRUG METABOLISM; HEADACHE; HUMAN; INSOMNIA; NEUROTRANSMITTER RELEASE; OBESITY; PRIORITY JOURNAL; REVIEW; XEROSTOMIA;

APPETITE DEPRESSANTS; CLINICAL TRIALS; CYCLOBUTANES; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; OBESITY; SEROTONIN UPTAKE INHIBITORS;

EID: 0032852016     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18319     Document Type: Review

References (72)

1. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.
2. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. NHLBI clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 1998;68:899-917.
3. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996;276: 1907-15.
4. Wolf AM, Colditz GA. The cost of obesity: the US perspective. PharmacoEconomics 1994;5(suppl 1):34-7.
5. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;110: 655-60.
6. Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997;337:602-6.
7. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
8. Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine (letter). N Engl J Med 1997;337:636.
9. McCann UD, Seiden LS, Rubin LJ, Ricaurte GA. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: a systematic review of the evidence. JAMA 1997;278: 666-72.
10. Package insert. Meridia (sibutramine). Mt. Olive, NJ: Knoll Pharmaceutical Co., 1997.
11. Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:575-84.
12. King DJ, DeVaney N. Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers. Br J Clin Pharmacol 1988;26:607-11.
13. Luscombe GP, Slater NA, Lyons MB, Wynne RD, Scheinbaum ML, Buckett WR. Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl. Psychopharmacology (Berl) 1990;100:345-9.
14. 3H]5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology 1993;32:737-43.
15. 3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 1996;35:63-70.
16. Heal DJ, Frankland ATJ, Gosden J, Hutchins LJ, Prow MR, Luscombe GP, Buckett WR. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacologic target for sibutramine. Psychopharmacology 1992:107:303-9.
17. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997;21(suppl 1):S25-9.
18. Gundlah C, Martin KF, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 1997;283:581-91.
19. 2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function. J Neural Transm 1995;102:35-46.
20. Scott G, Luscombe GP, Mason R. The effects of BTS 54 505, a metabolite of sibutramine, on monoamine and excitatory amino acid evoked responses in the rat dorsolateral geniculate nucleus in vivo. Br J Pharmacol 1994;111:97-102.
21. Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 1998;125:301-8.
22. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998;22(suppl 1):S18-28.
23. Davis R, Faulds D. Dexfenfluramine: an updated review of its therapeutic use in the management of obesity. Drugs 1996;52:696-724.
24. Silverstone T. Appetite suppressants: a review. Drugs 1992;43:820-36.
25. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and the therapeutic potential in obesity. Drugs 1992;43: 713-33.
26. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical β-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989;28:129-34.
27. Fantino M, Souquet AM. Effects of metabolites 1 and 2 of sibutramine on the short-term control of food intake in the rat (abstract). Int J Obes Relat Metab Disord 1995;19(suppl 2):145.
28. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121:1613-8.
29. Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997;121:1758-62.
30. 2-adrenoceptors exclusively by sibutramine hydrochloride. Psychopharmacology 1992;107:497-502.
31. 2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride. Psychopharmacology 1991;103:251-7.
32. 2-andrenoceptors in rat cortex. J Neurochem 1989; 53:1019-25.
33. Martin KF, Phillips I, Hearson M, Prow MR, Heal DJ. Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br J Pharmacol 1992;107:15-21.
34. Blundell JE, Halford JCG. Serotonin and appetite regulation. CNS Drugs 1998;9:473-95.
35. Halford JCG, Heal DJ, Blundell JE. Effects in the rat of sibutramine on food intake and the behavioral satiety sequence (abstract). Br J Pharmacol 1995;114(suppl):387P.
36. Stricker-Kongrad A, Burlet C, Souquet AM, Courrier A. Sibutramine effects on feeding behavior: a dose-dependence and microstructural analysis (abstract). Obes Res 1995;3(suppl 4):631S.
37. Stricker-Kongrad A, Souquet AM, Burlet C. Effects of sibutramine on feeding behaviour in obese and lean Zucker rats (abstract). Int J Obes Relat Metab Disord 1995;19(suppl 2):145.
38. Stricker-Kongrad A, Souquet AM, Burlet C. Effects of sibutramine on feeding behaviour in dietary-induced obesity: role of dietary constituents (abstract). Int J Obes Relat Metab Disord 1995:19(suppl 2): 145.
39. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998;6:1-11.
40. Connoley IP, Heal DJ, Stock MJ. A study in rats of the effects of sibutramine on food intake and thermogenesis (abstract). Br J Pharmacol 1995;114(suppl):388P.
41. Liu YL, Kashani SMZ, Heal DJ, Stock MJ. Effect of sibutramine on tissue glucose utilization in the rat (abstract). Br J Pharmacol 1996;117 (suppl):324P.
42. Connoley IP, Frost I, Heal DJ, Stock MJ. Role of β-adrenoceptors in mediating the thermogenic effects of sibutramine (abstract). Br J Pharmacol 1996;117(suppl):170P.
43. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998;6: 115-21.
44. Lean JEJ. Sibutramine - a review of clinical efficacy. Int J Obes Relat Metab Disord 1997;21(suppl 1):S30-6.
45. Johnson F, Velagapudi R, Hind I, Hinson J, Faulkner R. Effects of renal dysfunction on the pharmacokinetics of sibutramine and its metabolites (abstract). J Clin Pharmacol 1999;37:865.
46. Hind I, Mangham JE, Ghani SP, Haddock RE, Garratt CJ, Jones RW. Sibutramine pharmacokinetics in young and elderly subjects. Eur J Clin Pharmacol 1999;54:847-9.
47. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-7.
48. Drouin P, Hanotin C, Courcier S, Leutenegger E. A dose ranging study: efficacy and tolerability of sibutramine in weight loss (abstract). Int J Obes Relat Metab Disord 1994;18(suppl 2):60.
49. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998;22:32-8.
50. Jones SP, Newman BM, Romanec FM. Sibutramine hydrochloride: weight loss in overweight subjects (abstract). Int J Obes Relat Metab Disord 1994;18(suppl 2):61.
51. Bray GA, Gordon DH, Heidingsfelder S, Macchiavelli R, Wilson K. Double-blind randomized trial of sibutramine in overweight subjects (abstract). Int J Obes Relat Metab Disord 1995;19(suppl 2):144.
52. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4:263-70.
53. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain A, Kaise PE, et al. Sibutramine: dose response and long-term efficacy in weight loss, a double-blind study (abstract). Int J Obes Relat Metab Disord 1994;18 (suppl 2):60.
54. Mendels J, Blackburn GL, Bray GA, Ferguson JM, Greenway FL, Jain A, et al. Sibutramine and long-term weight loss: percentage of patients losing 5% and 10% of baseline weight (abstract). Int J Obes Relat Metab Disord 1994;18(suppl 2):61.
55. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98.
56. Jones SP, Smith IG, Kelly F, Gray JA. Long-term weight loss with sibutramine (abstract). Int J Obes Relat Metab Disord 1995;19(suppl 2):S41.
57. Jones SP, Heath MJ. Long term weight loss with sibutramine: 5% responders (abstract). Int J Obes Relat Metab Disord 1996;20(suppl 4): 157.
58. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutnegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.
59. Kelly F, Wade AG, Jones SP, Johnson SG. Sibutramine hydrochloride vs dexfenfluramine: weight loss in obese subjects (abstract). Int J Obes Relat Metab Disord 1994;18(suppl 2):S61.
60. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes Res 1998;6:285-91.
61. Hazenberg BP, Johnson SG, Kelly F. Sibutramine in the treatment of obese subjects with hypertension (abstract). Int J Obes Relat Metab Disord 1996;20(suppl 4):S156.
62. Griffiths J, Brynes AE, Frost G, Bloom SR, Finer N, Jones SP, et al. Sibutramine in the treatment of overweight non-insulin dependent diabetics (abstract). Int J Obes Relat Metab Disord 1995;19(suppl 2):41.
63. Shepherd G, Fitchet M, Kelly F. Sibutramine: a meta-analysis of the change in fasting plasma glucose in patients with a high baseline fasting value (abstract). Int J Obes Relat Metab Disord 1997;21(suppl 2):S54.
64. Fitchet M. Shepherd G, Kelly F. Sibutramine: a meta-analysis of changes in fasting serum lipids in placebo-controlled studies (abstract). Int J Obes Relat Metab Disord 1997;21(suppl 2):S53.
65. Oya M, Dominguez R, Heath M. The effects of sibutramine induced weight loss in obese subjects with hyperlipidemia (abstract). Int J Obes Relat Metab Disord 1997;21(suppl 2):S54.
66. Hansen DL. Effects of sibutramine in blood lipids (abstract). Int J Obes Relat Metab Disord 1997;21(suppl 2):S55.
67. Food and Drug Administration-Endocrinologic and Metabolic Drugs Advisory Committee Meeting Proceedings. Bethesda, MD: September 26, 1996.
68. Gosden J, Buckett WR, Heal DJ. D-Amphetamine-cued drug discrimination in rats: predictive value for detecting stimulant drugs of abuse (abstract). Br J Pharmacol 1996;117(suppl):169P.
69. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998;18:231-6.
70. Back DJ, Fearn R, Oliver S, Stott DA, Wynne RD. Lack of effect of sibutramine on the efficacy of oral contraceptive steroids in healthy women. Int J Pharm Med 1997;11:71-6.
71. Wynne RD, Braybrooke RM, Brown T, Jones S, Stott DA, Thornton GM. A single-dose, placebo-controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers. Int J Pharm Med 1997;11:65-70.
72. 1998 Drug topics red book. Montvale, NJ: Medical Economics Co., 1998:428.